Background. There is little information in the literature describing the relationship between posttransplantation lymphoproliferative disorder (PTLD) incidence and presentation with both recipient Epstein-Barr virus (EBV) serostatus and EBV status of PTLD histology, particularly in the late posttransplantation period. Methods. This study reports the largest UK single-center, single-organ analysis of PTLD to date in a retrospective cohort study of 80 cases occurring in 4189 adult renal transplant recipients. Results. The incidence rate was 2.6 cases per 1000 patient-years (95% confidence interval [95% CI], 2.1Y3.2) for PTLD, 1.8 (95% CI, 1.4Y2.4) for non-Hodgkin's lymphoma, and 0.2 (95% CI, 0.07Y4.2) for Hodgkin's lymphoma. NonHodgkin's lymphoma occurred at a rate 7.6 times that of the adult general population in England, whereas the rate for Hodgkin's lymphoma was 5.9 times. The incidence of PTLD was highest during the 10th to 14th posttransplantation years. Early-onset disease was associated with EBV-seronegative recipient status, EBV-positive histology, and the involvement of extranodal sites. PTLD occurring in EBV-seronegative recipients was associated with EBV nuclear antigen antibody deficiency, polymorphic disease, and the involvement of extranodal sites. EBV-negative histology occurred in 32% of cases at a median time to presentation of 109 months. PTLD involving the allograft, central nervous system, and skin was uncommon and occurred late. Conclusion. The incidence of PTLD is highest in the late posttransplantation period. Close clinical surveillance and education for transplant recipients is required for the duration of time while immunosuppressed. Failure to detect EBV DNA in blood should not reassure, particularly in patients with symptoms such as abdominal pain, oropharyngeal complaints, neck lumps, and B-symptoms.
There is little information in the literature describing relationships between PTLD incidence and presentation with both recipient EBV serostatus and EBV status of histology, particularly in the late posttransplantation period. Focus on late PTLD in adult kidney transplant recipients is increasingly important as median graft and patient survival times increase (now 980% at 5 years).
To address the points above, we performed an observational cohort study of our renal transplant population to identify PTLD cases, define incidence rates of PTLD, and describe the variation in clinical presentation, including organ involvement. We analyzed the timing of disease presentation with reference to EBV recipient serostatus and tissue EBV status, comparing those patients with early (G1 year), late (91 year), and very late (910 years) onset of disease.
RESULTS

Incidence of Posttransplantation Lymphoproliferative Disorder
A summary of the incidence data is shown in Table 1 .
The median follow-up time for all transplant recipients was 2058 days (5.6 years; interquartile range [IQR], 676Y3983). PTLD occurred in 80 recipients in 30,867 patient-years, giving an incidence rate of 2.6 cases per 1000 patient-years. NonHodgkin's lymphoma (NHL) was seen more frequently than Hodgkin's lymphoma (rate ratio, 9.7). NHL occurred at a rate ratio of 7.6 and Hodgkin's lymphoma at 5.9 that of the general population (16) . PTLD occurred more frequently in males than females (P=0.039) and there was a trend toward increased rates with age at transplantation. No significant differences in incidence rates were detected between different eras of transplantation (Tables 1 and 2) .
Incidence rates were associated with time from transplantation. The second to fourth years after transplantation were used as a reference group because this period was expected to have the lowest incidence of PTLD. We observed a bimodal pattern of presentation with rates in the first year after transplantation higher than the reference period (rate ratio, 2.7; 95% confidence interval [95% CI], 1.1Y6.1; P=0.0098) and peak incidence occurring later between 10 and 14 years after transplantation (rate ratio, 3.4; 95% CI, 1.7Y7.3; P=0.032; Fig. 1 ).
Posttransplantation Lymphoproliferative Disorder Clinical Characteristics
The characteristics of the PTLD population are summarized in Table 3 .
The median time from transplantation to presentation of PTLD for the 80 cases was 74 months (6.1 years; IQR, 28Y131). Cases presented early (within 1 year after transplantation) in 12 of 80 (15%) and late (91 year) in 68 of 80 (85%). Very late presentations (910 years) occurred in 24 of 80 (30%), with 3 (4%) beyond the 20th posttransplantation year.
Early-Onset Disease
Early-onset disease (G1 year) was associated with Fig. 2A ), and nearly half of all cases in the seronegative group occurred during the first transplantation year. Early-onset disease occurred almost entirely in seronegative recipients (90% cases with known serostatus; OR, 32.4 for seronegative versus seropositive; 95% CI, 3.7Y287; PG0.0001; Fig. 2A EBV status of PTLD histology was available for 56 of 80 cases, of which 18 of 56 (32%) were EBV negative. EBVnegative PTLD was unusual in the early posttransplantation period and case numbers increased with time from transplantation: 1 of 11 (9%) in the first year, 3 of 8 (38%) in the second to fourth years, 6 of 12 (50%) in the fifth to ninth years, and 9 of 26 (35%) cases beyond 10 years (Fig. 2B) . EBV was detectable in blood at diagnosis in 55% of EBV-negative histology disease. EBV-negative PTLD was seen in 24% of seronegative recipients and 37% of seropositive recipients (P=0.51). Seronegative recipients who developed EBV-negative PTLD all had evidence of seroconversion (detectable IgG to EBV VCA) at diagnosis.
Epstein-Barr VirusYPositive Histology Posttransplantation Lymphoproliferative Disorder PTLD tissue was EBV positive in 38 of 56 (68%) of cases, including 91% (10 of 11) of all cases presenting within 1 year of transplantation. Detectable EBV viral loads in blood were seen in 96% of cases. The median time to presentation for patients with EBV-positive PTLD was slightly but not significantly earlier than EBV negative (89 vs. 109 months).
Presenting Symptoms and Organ Involvement at Presentation
The demographics, histology, presenting clinical symptoms, and sites of disease at the time of diagnosis are shown in Table 3 . Symptoms occurring with the greatest frequency included neck swelling, abdominal pain, oropharyngeal complaints, and occurrence of B-symptoms.
Survival
Overall patient survival at 1, 5, and 10 years was 66%, 50%, and 37%, respectively, with a median survival of 1253 days from diagnosis. A complete response to treatment was seen in 46 of 80 (58%) of patients, of whom 11 (24%) subsequently relapsed at a median time from diagnosis of 325 days (IQR, 214Y726) and 8 (17%) lost their graft at a median time of 896 days (IQR, 363Y1370) from diagnosis. (70) 8 (67) 48 (71) 14 (74) 29 (78) 15 (79) 24 (63) Mean age 49 (14) 52 (14) 49 (14) 48 (17) 51 (11) 53 (15) 50 ( 1 (8) 4 (6) 1 (5) 4 (11) 1 (5) 4 (11) Polymorphic 12 (15) 4 (33) 8 (12) 6 (32) 3 (8) 3 (16) 7 (18) Monomorphic 57 (71) 7 (59) 50 (74) 11 (58) 27 (73) 14 (74) 23 (60) Hodgkin's 6 (8)
1 (5) 3 (8) 1 (5) 4 (11) Clinical symptoms at presentation Neck swelling 31 (42) 5 (42) 25 (41) 9 (50) 17 (49) 9 (56) 17 (46) Oropharynx 14 (19) 4 (35) 10 (16) 4 (22) 7 (20) 1 (6) 11 (30) Abdominal pain
19 (26) 4 (33) 14 (23) 5 (28) 7 (20) 8 (47) 6 (16) B-symptoms 51 (65) 9 (75) 42 (69) 4 (78) 22 (63) 13 (81) 23 (62) Disease sites at presentation Single site 30 (41) 3 (25) 27 (44) 5 (28) 18 (51) 8 (50) 11 (30) Extranodal 49 (66) 11 (92) 38 (62) 15 (83) 18 (51) 9 (53) 24 (65) Ann Arbor score Q3
28 (38) 8 (67) 19 (31) 11 (61) 10 (29) 7 (41) 14 (38) Neck 31 (42) 6 (50) 25 (41) 8 (44) 18 (51) 9 (56) 17 (46) Oropharynx 15 (20) 3 (25) 12 (20) 4 (22) 8 (23) 2 (13) 11 (30) Liver 12 (16) 5 (42) 7 (11) 7 (39) 4 (11) 2 (13) 7 (19) Spleen 10 (14) 6 (50) 4 (7) 7 (39) 3 (9) 3 (19) 5 (14) Gastrointestinal tract (all)
15 (20) 5 (42) 10 (16) 3 (17) 5 (14) 5 (29) 6 (16) Bowel 10 (14) 3 (25) 7 (11) 2 (11) 4 (11) 4 (24) 4 (11) Stomach 5 (7) 2 (17) 3 (5) 1 (6) 1 (3) 1 (6) 2 ( 1 (6) 5 (14) 2 (13) 4 ( Graft survival at 1, 5, and 10 years from diagnosis in those who had a complete response was 96%, 82%, and 77%, respectively.
DISCUSSION
This study reports the largest UK single-center, singleorgan analysis of PTLD to date. PTLD presented up to 24 years after transplantation in 1.9% of adult kidney transplant recipients. Our incidence rates were similar to those reported recently by Swedish (6), French (12), US (15) , and UK (5) studies. Analysis of PTLD timing in relation to EBV serostatus confirmed the increased risk for seronegative recipients in the first year but also highlighted a persistently increased risk for these patients in the late posttransplantation period. This study also draws attention to differences in clinical presentation for disease occurring early, late, and very late in EBVseronegative and EBV-seropositive recipients and for EBV histology-positive and histology-negative PTLD.
Compared with the adult general population, we found an eightfold increased risk of NHL and sixfold increased risk of Hodgkin's lymphoma. EBV positivity was found in approximately 40% of Hodgkin's lymphoma cases (17) and 26% of B-cell NHL cases (18) in the general population. In our series, EBV positivity was more prevalent and seen in 80% of early lesions, 80% of Hodgkin's lymphoma, 70% of polymorphic cases, and 64% of monomorphic PTLD cases.
High rates of lymphoma in solid organ transplant recipients are linked to the use of specific immunosuppressive agents, including calcineurin inhibitors (4, 5), and T-cellYdepleting antibodies (2, 14, 15). Caillard et al. observed a fall in lymphoma incidence more recently in France, which may have been due to reduced use of T-cellYdepleting antibodies. We did not observe any statistically significant changes in recent times in our series, although we have never used T-cellYdepleting agents as induction therapy. Compared with the French registry (2012) (12), a similar proportion of PTLD cases in our series involved gastrointestinal tract disease. We experienced less early-onset disease (15% vs. 48%), CNS disease (5% vs. 20%), and graft involving disease than the French series (3% vs. 24%). Reasons for these differences may be due to a low French rate of recipient-seronegative status at transplantation (only 3%), with only 16% of French cases occurring in seronegative recipients compared with 34% in our series. Further, the French had a high rate of ATG induction, 54% in controls and 66% in cases, compared with only 13% of our cases.
Our data confirm the first year after transplantation as a period of high incidence of PTLD for EBV-seronegative recipients (12, 13, 15) . French and US registry data have also associated EBV-seronegative status with an increased hazard risk of not only early but also late PTLD. In our series, 90% of early and a further 22% of all late PTLD occurred in seronegative recipients despite them making up less than 10% of all adult kidney transplant recipients in our unit. The small number of seronegative recipients and relatively high proportion of cases presenting in this group in the first year and later (950% of cases) suggests that these individuals should remain under close clinical surveillance for the duration of their transplant life. Disease occurring in our seropositive recipients was unusual in the first few years. Seropositive recipients had a significantly greater likelihood of PTLD in the late follow-up (7) 2 (17) 3 (5) 3 (17) 0 1 (6) 2 ( (8) 1 (8) 5 (8) 3 (17) 1 (3) 1 (6) 3 ( period than in the first 4 years. The etiology of late PTLD appears complex and the incidence of late disease may increase over the next 10 years as transplantation rates increase and improved graft survival results in the exposure of recipients to immunomodulatory medication for longer periods of time. Late disease may relate to impaired immune responses at the time of primary infection, duration of exposure to immunosuppression, age, immunosenescence, and perhaps other infective agents. Cytomegalovirus infection has been associated with EBV-negative PTLD (12) . Currently, the UK (2011) (19) and Kidney Disease: Improving Global Outcomes (2009) (20) guidelines advocate that high-risk EBV donor-positive, recipient-negative patients have EBV viral load monitoring until the end of the first year and that total immunosuppression is reduced when EBV titers rise significantly. However, in the United Kingdom, detection of whole-blood EBV DNA by polymerase chain reaction in the first 90 days after transplantation was reported in 50% of seronegative recipients and 56% of all adult renal transplant recipients, without the presentation of PTLD during a 2-year follow-up (21) . In 20 EBV donor-positive, recipient-negative transplants receiving ATG induction, Martin et al. (22) reported detectable EBV DNA in plasma in 74% of patients in the first year, of which 1 of 20 developed PTLD. Screening for detectable EBV viral loads beyond the first year is not yet standard practice. Detection of EBV DNA in whole blood is reported in up to 36% of stable renal transplant recipients at any one time and the prevalence of DNAemia may increase with time from transplantation (23) . Further, 15% of all our late cases of PTLD had no detectable EBV DNA in their blood at the time of diagnosis. Whole-blood screening for EBV DNA is sensible and logistically feasible in seronegative recipients in the first year, but viral load detection alone does not identify PTLD cases. Close clinical surveillance is also required in the high-risk patient for the duration of their transplant life. In our series, we identified clinical features that may help to prompt urgent investigations. Common symptoms included neck pain and swelling, oropharyngeal complaints, abdominal pain, obstructive symptoms, and B-symptoms. Disease presenting early and in the seronegative patient often involved multiple sites, extranodal sites, liver, spleen, and the gastrointestinal tract. Disease involving the CNS, skin, and soft tissue tended to occur late. Very late disease (910 years) may have a high rate of relapse and involve neck, oropharynx, and sites of chronic inflammation.
Limitations of the Study
EBV serostatus was missing for 32% of the cases and EBV tissue status for 30% of the cases. Data could not be collected if absent from medical records and where stored serum or histology blocks were not available for analysis. PTLD presentations after 2000 had more complete data sets: serostatus 84% (after 2000) versus 47% (before 2000) and tissue status 86% versus 47%. We have no evidence to suggest any bias attached to the missing data.
Individuals whose first presentation of PTLD followed the onset of graft failure and return to dialysis were not included in the study. Although most wean or discontinue immunosuppression, a number remain on low-level immunosuppression and retain their graft, a potential site of chronic inflammation, and may continue to have an increased risk of lymphoma development. Comparison with rates of lymphoma in dialysis patients and individuals with failed kidney transplants on dialysis would be interesting.
Patients aged 18 or less years at the time of PTLD diagnosis and/or the time of transplantation were also excluded from this study. Data and characteristics of late presenting PTLD in the paediatric group are also lacking. Statistical analysis of differences in characteristics between patient subgroups (Table 3) is limited by the small numbers of cases. This is reflected in the wide 95% CIs seen, for example, in comparisons between early-and lateonset disease.
MATERIALS AND METHODS
Identification of Posttransplantation Lymphoproliferative Disorder Cases
Inclusion criteria for the study were age more than 18 years and a functioning renal allograft at the time of diagnosis. All PTLD cases were classified according to the 2008 World Health Organization classification as early, polymorphic, monomorphic, or Hodgkin's disease (24) . Multiple myeloma was not included. PTLD histologic classification and subclassification and PTLD tumor EBV status based on immunohistochemical staining or in situ hybridization for EBV-encoded RNA were performed by regional specialist hematopathologists.
Data were abstracted from the Regional Tissue Typing Laboratory database and through a comprehensive search of pathology databases. Cases of PTLD occurring from August 1, 2009 onward were identified prospectively following referral to regional hemato-oncology. In the case of individuals who transferred their care to other units outside our region following transplantation (n=175), outcome data including occurrence of graft loss (23 of 175) and PTLD (n=4) was obtained from the National Health Service Blood and Transplant Registry. PTLD cases identified were verified with the unit providing follow-up care.
Incidence of Posttransplantation Lymphoproliferative Disorder
Patient-years of follow-up were calculated for all individuals receiving a kidney transplant between March 22, 1968 and February 29, 2012 . Censorship occurred at the date of disease onset for PTLD cases and for all others at the onset of graft failure or death or the end of the follow-up period. Incidence rates were expressed as the number of cases over the number of patient-years at risk and then as cases per 1000 patient-years. Poisson distribution with 95% CIs were calculated for the estimated rates.
We calculated the incidence of PTLD in our adult transplant population and compared with age-standardized rates of Hodgkin's lymphoma and NHL in the general population (ages 919 years) in England (total population n=39,104,000) for the calendar year 2008. Lymphoma incidence in the general population was obtained for the International Classification of Disease, Tenth Edition code C81 (Hodgkin's lymphoma) and codes C82Y85 and 96 (NHL) from the North West Cancer Intelligence Service (personal communication) and UK Cancer Intelligence Service report (2011) for cases occurring in 2008 and registered by September 2010 (16) .
Change in incidence rates of PTLD with increasing time from transplantation and between different eras of immunosuppression was analyzed, including 1990 to 1994 (cyclosporine, azathioprine, and prednisolone), 1995 to 1999 (cyclosporine, mycophenolate, and prednisolone), 2000 to 2004 (tacrolimus, mycophenolate and prednisolone), and since 2004 in line with National Institute for Clinical Excellence guidance (basiliximab induction followed by calcineurin inhibition with tacrolimus and added mycophenolate, azathioprine, and corticosteroids depending on immunologic risk) (25) . Lymphocyte-depleting antibodies are not used as induction agents in our unit and are reserved for steroid-resistant and vascular rejection. Acute rejection rates with current immunosuppressive protocols are less than 10% and the use of ATG has decreased in recent times. Antiviral prophylaxis is given to individuals at high risk of cytomegalovirus disease (donor-positive, recipient-negative and those receiving lymphocyte-depleting antibodies).
Clinical Presentation
Groups were compared using mean (standard deviation) for normally distributed variables and median (IQR) for skewed data. Group comparisons between early-and late-onset presentations and disease presenting in EBVseronegative and EBV-seropositive recipients used chi-square testing for categorical variables and Student's two-sided t test for continuous variables.
Group comparisons and univariate analyses were performed using GraphPad Prism 5 software.
Epstein-Barr Virus Serostatus and Timing of Posttransplantation Lymphoproliferative Disorder
Where EBV serostatus was not known (pre-2008 donors and recipients were not routinely screened for EBV serostatus), stored (j80-C) serum samples taken on the day of transplantation were obtained from the Regional Tissue Typing Laboratory, and IgG antibody status to EBV VCA and EBNA-1 antigens was determined.
Kaplan-Meier time to event curves were used to graphically illustrate the cumulative time to presentation for EBV-seronegative and EBV-seropositive recipients ( Fig. 2A) and tissue EBV-positive and tissue EBV-negative recipients (Fig. 2B) . Comparison of the curves used the log-rank test (GraphPad Prism 5 software).
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